Locations:
SearchChoice of testing ‘is becoming interesting’
With increasing genetic insights into hereditary breast cancer, clinicians must decide which of a variety of diagnostic and prognostic genetic test they should offer patients and their families.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
In this video, Holly Pederson, MD, Director of Cleveland Clinic’s Medical Breast Program and Hereditary High-Risk Program, discusses red flags that indicate heightened risk of hereditary breast cancer, and the range of genetic tests that are available.
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients